Literature DB >> 18653826

Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases.

Marius E Kraenzlin1, Claude A Kraenzlin, Christian Meier, Cecilia Giunta, Beat Steinmann.   

Abstract

BACKGROUND: The pyridinium cross-links pyridinoline (PYD) and deoxypyridinoline (DPD) are established markers of bone resorption. We evaluated the analytical and clinical performance of a commercially available PYD HPLC assay and established reference intervals in children and adults.
METHODS: We used a commercially available reagent set (Chromsystems Instruments & Chemicals) to measure PYD and DPD in 319 healthy controls (156 premenopausal women, 80 healthy men, and 83 healthy children age 1 month to 14 years) and 397 patients with metabolic bone diseases (postmenopausal osteoporosis, n = 175; male osteoporosis, n = 176; hyperparathyroidism, n = 17; hyperthyroidism, n = 19; Paget disease, n = 10).
RESULTS: The mean intraassay and interassay CVs were <6% and <8% for both PYD and DPD, respectively. The reference interval was constant for premenopausal women in the age group 20-49 years. In men, cross-link values peaked at 20-29 years and decreased thereafter. Women with postmenopausal osteoporosis had significantly higher PYD (51%) and DPD (58%) values compared to premenopausal women. Similar results were found in osteoporotic men. In children the highest values were found in the first weeks and months after birth, followed by a decrease of 50%-60% at age 11-14 years. In metabolic bone diseases cross-link concentrations were significantly increased. The DPD:PYD ratio (mean value approximately 0.2) was remarkably constant in all populations evaluated.
CONCLUSIONS: The automated HPLC assay is a precise and convenient method for PYD and DPD measurement. We established reference intervals for adult women and men and for children up to 14 years old. The cross-link concentrations we determined by use of this HPLC method confirm its clinical value in enabling identification of increased bone resorption in patients with metabolic bone diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18653826     DOI: 10.1373/clinchem.2008.105262

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  14 in total

1.  Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China.

Authors:  X-Y Wu; H Zhang; H Xie; X-H Luo; Y-Q Peng; L-Q Yuan; R-C Dai; Z-F Sheng; X-P Wu; E-Y Liao
Journal:  Osteoporos Int       Date:  2013-07-23       Impact factor: 4.507

2.  Molecular Consequences of the SERPINH1/HSP47 Mutation in the Dachshund Natural Model of Osteogenesis Imperfecta.

Authors:  Uschi Lindert; Mary Ann Weis; Jyoti Rai; Frank Seeliger; Ingrid Hausser; Tosso Leeb; David Eyre; Marianne Rohrbach; Cecilia Giunta
Journal:  J Biol Chem       Date:  2015-05-24       Impact factor: 5.157

3.  Mutations in FKBP14 cause a variant of Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss.

Authors:  Matthias Baumann; Cecilia Giunta; Birgit Krabichler; Franz Rüschendorf; Nicoletta Zoppi; Marina Colombi; Reginald E Bittner; Susana Quijano-Roy; Francesco Muntoni; Sebahattin Cirak; Gudrun Schreiber; Yaqun Zou; Ying Hu; Norma Beatriz Romero; Robert Yves Carlier; Albert Amberger; Andrea Deutschmann; Volker Straub; Marianne Rohrbach; Beat Steinmann; Kevin Rostásy; Daniela Karall; Carsten G Bönnemann; Johannes Zschocke; Christine Fauth
Journal:  Am J Hum Genet       Date:  2012-01-19       Impact factor: 11.025

4.  Mutations in PRDM5 in brittle cornea syndrome identify a pathway regulating extracellular matrix development and maintenance.

Authors:  Emma M M Burkitt Wright; Helen L Spencer; Sarah B Daly; Forbes D C Manson; Leo A H Zeef; Jill Urquhart; Nicoletta Zoppi; Richard Bonshek; Ioannis Tosounidis; Meyyammai Mohan; Colm Madden; Annabel Dodds; Kate E Chandler; Siddharth Banka; Leon Au; Jill Clayton-Smith; Naz Khan; Leslie G Biesecker; Meredith Wilson; Marianne Rohrbach; Marina Colombi; Cecilia Giunta; Graeme C M Black
Journal:  Am J Hum Genet       Date:  2011-06-10       Impact factor: 11.025

5.  Kyphoscoliotic type of Ehlers-Danlos Syndrome (EDS VIA) in six Egyptian patients presenting with a homogeneous clinical phenotype.

Authors:  Ebtesam M Abdalla; Marianne Rohrbach; Céline Bürer; Marius Kraenzlin; Hazem El-Tayeby; Mervat F Elbelbesy; Amira Nabil; Cecilia Giunta
Journal:  Eur J Pediatr       Date:  2014-10-03       Impact factor: 3.183

6.  Spondylocheiro dysplastic form of the Ehlers-Danlos syndrome--an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13.

Authors:  Cecilia Giunta; Nursel H Elçioglu; Beate Albrecht; Georg Eich; Céline Chambaz; Andreas R Janecke; Heather Yeowell; MaryAnn Weis; David R Eyre; Marius Kraenzlin; Beat Steinmann
Journal:  Am J Hum Genet       Date:  2008-06       Impact factor: 11.025

Review 7.  Bone turnover markers: understanding their value in clinical trials and clinical practice.

Authors:  R Civitelli; R Armamento-Villareal; N Napoli
Journal:  Osteoporos Int       Date:  2009-02-04       Impact factor: 4.507

8.  Ehlers-Danlos Syndrome Type VI in a 17-Year-Old Iranian Boy with Severe Muscular Weakness - A Diagnostic Challenge?

Authors:  Ariana Kariminejad; Bita Bozorgmehr; Alireza Khatami; Mohamad-Hasan Kariminejad; Cecilia Giunta; Beat Steinmann
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

9.  Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation.

Authors:  Marianne Rohrbach; Anthony Vandersteen; Uluç Yiş; Gul Serdaroglu; Esra Ataman; Maya Chopra; Sixto Garcia; Kristi Jones; Ariana Kariminejad; Marius Kraenzlin; Carlo Marcelis; Matthias Baumgartner; Cecilia Giunta
Journal:  Orphanet J Rare Dis       Date:  2011-06-23       Impact factor: 4.123

10.  Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men.

Authors:  El Hadidy M El Hadidy; Mohamed Ghonaim; Soma Sh Abd El Gawad; Mohamed Abou El Atta
Journal:  BMC Endocr Disord       Date:  2011-08-06       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.